Is QURE or DBVT more profitable?

uniQure has a net margin of -1,350.73% compared to DBV Technologies' net margin of -3,506.53%. uniQure's return on equity of -111.96% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% DBV Technologies -3,506.53% -119.33% -84.43%

Does the media prefer QURE or DBVT?

In the previous week, uniQure and uniQure both had 3 articles in the media. DBV Technologies' average media sentiment score of 1.07 beat uniQure's score of 0.78 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLDX or DBVT?

In the previous week, Celldex Therapeutics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for Celldex Therapeutics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat Celldex Therapeutics' score of 1.04 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DBVT or IMNM more profitable?

Immunome has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Immunome's return on equity of -50.56% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% Immunome N/A -50.56% -46.93%

Does the media favor DBVT or IMNM?

In the previous week, Immunome had 8 more articles in the media than DBV Technologies. MarketBeat recorded 11 mentions for Immunome and 3 mentions for DBV Technologies. Immunome's average media sentiment score of 1.16 beat DBV Technologies' score of 1.07 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DBVT or NAMS?

In the previous week, NewAmsterdam Pharma had 15 more articles in the media than DBV Technologies. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat NewAmsterdam Pharma's score of 0.39 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Is ZLAB or DBVT more profitable?

Zai Lab has a net margin of -41.86% compared to DBV Technologies' net margin of -3,506.53%. Zai Lab's return on equity of -27.43% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% DBV Technologies -3,506.53% -119.33% -84.43%

Does the media prefer ZLAB or DBVT?

In the previous week, DBV Technologies had 1 more articles in the media than Zai Lab. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Zai Lab. DBV Technologies' average media sentiment score of 1.07 beat Zai Lab's score of 0.82 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DBV Technologies (DBVT) Competitors

$11.85 -1.12 (-8.64%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.86 +0.01 (+0.04%)

As of 09/11/2026 05:55 PM Eastern

Compare

DBVT vs. QURE, CLDX, IMNM, NAMS, and ZLAB

Should you buy DBV Technologies stock or one of its competitors? DBV Technologies's main competitors and comparable companies include uniQure (QURE), Celldex Therapeutics (CLDX), Immunome (IMNM), NewAmsterdam Pharma (NAMS), and Zai Lab (ZLAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DBV Technologies compare to uniQure?

uniQure (NASDAQ:QURE) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, uniQure and uniQure both had 3 articles in the media. DBV Technologies' average media sentiment score of 1.07 beat uniQure's score of 0.78 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, indicating that its share price is 195% less volatile than the broader market.

DBV Technologies has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A

uniQure has a net margin of -1,350.73% compared to DBV Technologies' net margin of -3,506.53%. uniQure's return on equity of -111.96% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

uniQure presently has a consensus price target of $65.00, indicating a potential upside of 46.03%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 309.28%. Given DBV Technologies' higher probable upside, analysts clearly believe DBV Technologies is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

78.8% of uniQure shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

uniQure beats DBV Technologies on 10 of the 15 factors compared between the two stocks.

How does DBV Technologies compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Celldex Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, indicating that its stock price is 195% less volatile than the broader market.

In the previous week, Celldex Therapeutics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for Celldex Therapeutics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat Celldex Therapeutics' score of 1.04 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics presently has a consensus target price of $56.42, indicating a potential upside of 52.89%. DBV Technologies has a consensus target price of $48.50, indicating a potential upside of 309.28%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Celldex Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Celldex Therapeutics' return on equity of -52.35% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

DBV Technologies has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$158K	18,340.23	-$258.76M	-$4.35	N/A
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A

71.7% of DBV Technologies shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Celldex Therapeutics beats DBV Technologies on 10 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Immunome?

DBV Technologies (NASDAQ:DBVT) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

In the previous week, Immunome had 8 more articles in the media than DBV Technologies. MarketBeat recorded 11 mentions for Immunome and 3 mentions for DBV Technologies. Immunome's average media sentiment score of 1.16 beat DBV Technologies' score of 1.07 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DBV Technologies has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A
Immunome	N/A	N/A	-$212.39M	-$2.53	N/A

Immunome has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Immunome's return on equity of -50.56% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Immunome	N/A	-50.56%	-46.93%

DBV Technologies has a beta of -0.95, indicating that its stock price is 195% less volatile than the broader market. Comparatively, Immunome has a beta of 2.13, indicating that its stock price is 113% more volatile than the broader market.

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 309.28%. Immunome has a consensus target price of $34.64, suggesting a potential upside of 40.40%. Given DBV Technologies' higher probable upside, equities analysts plainly believe DBV Technologies is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Immunome beats DBV Technologies on 10 of the 15 factors compared between the two stocks.

How does DBV Technologies compare to NewAmsterdam Pharma?

DBV Technologies (NASDAQ:DBVT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, NewAmsterdam Pharma had 15 more articles in the media than DBV Technologies. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat NewAmsterdam Pharma's score of 0.39 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DBV Technologies has a beta of -0.95, meaning that its share price is 195% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

DBV Technologies has a net margin of -3,506.53% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 309.28%. NewAmsterdam Pharma has a consensus target price of $49.73, suggesting a potential upside of 118.10%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

DBV Technologies has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A
NewAmsterdam Pharma	$7.12M	382.73	-$203.82M	-$2.16	N/A

Summary

NewAmsterdam Pharma beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Zai Lab currently has a consensus price target of $37.25, indicating a potential upside of 54.31%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 309.28%. Given DBV Technologies' higher probable upside, analysts clearly believe DBV Technologies is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, DBV Technologies had 1 more articles in the media than Zai Lab. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Zai Lab. DBV Technologies' average media sentiment score of 1.07 beat Zai Lab's score of 0.82 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a net margin of -41.86% compared to DBV Technologies' net margin of -3,506.53%. Zai Lab's return on equity of -27.43% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Zai Lab has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, suggesting that its share price is 195% less volatile than the broader market.

DBV Technologies has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	5.97	-$175.54M	-$1.71	N/A
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A

Summary

Zai Lab beats DBV Technologies on 9 of the 17 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$815.49M	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-3.38	14.25	275.24	25.29
Price / Sales	132.11	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	2.82	15.12	10.33	6.20
Net Income	-$146.95M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-12.03%	-4.34%	-3.32%	-2.35%
1 Month Performance	-16.20%	-0.02%	-0.41%	-2.77%
1 Year Performance	20.06%	40.64%	19.21%	7.63%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	3.4515 of 5 stars	$11.85 -8.6%	$48.50 +309.3%	+21.0%	$815.49M	$5.64M	N/A	80	News Coverage Positive News Analyst Forecast High Trading Volume
QURE uniQure	3.5253 of 5 stars	$45.93 +3.2%	$65.00 +41.5%	+162.8%	$3.19B	$16.10M	N/A	500	Gap Down
CLDX Celldex Therapeutics	2.1177 of 5 stars	$39.04 -1.6%	$56.08 +43.6%	+46.4%	$3.07B	$1.54M	N/A	150	News Coverage Positive News Analyst Forecast
IMNM Immunome	3.1249 of 5 stars	$26.88 +0.4%	$34.64 +28.9%	+154.9%	$3.06B	$6.94M	N/A	40	Positive News Analyst Forecast Gap Down
NAMS NewAmsterdam Pharma	2.8616 of 5 stars	$24.85 -2.2%	$49.73 +100.1%	-14.3%	$2.98B	$22.50M	N/A	4	News Coverage Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. QURE, CLDX, IMNM, NAMS, and ZLAB

How does DBV Technologies compare to uniQure?

Summary

How does DBV Technologies compare to Celldex Therapeutics?

Summary

How does DBV Technologies compare to Immunome?

Summary

How does DBV Technologies compare to NewAmsterdam Pharma?

Summary

How does DBV Technologies compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. QURE, CLDX, IMNM, NAMS, and ZLAB

How does DBV Technologies compare to uniQure?

Does the media prefer QURE or DBVT?

Which has more risk and volatility, QURE or DBVT?

Which has higher valuation and earnings, QURE or DBVT?

Is QURE or DBVT more profitable?

Do analysts prefer QURE or DBVT?

Do insiders and institutionals believe in QURE or DBVT?

Summary

How does DBV Technologies compare to Celldex Therapeutics?

Which has more risk & volatility, CLDX or DBVT?

Does the media favor CLDX or DBVT?

Do analysts prefer CLDX or DBVT?

Is CLDX or DBVT more profitable?

Which has preferable earnings & valuation, CLDX or DBVT?

Do insiders & institutionals believe in CLDX or DBVT?

Summary

How does DBV Technologies compare to Immunome?

Does the media favor DBVT or IMNM?

Which has better earnings & valuation, DBVT or IMNM?

Is DBVT or IMNM more profitable?

Which has more risk and volatility, DBVT or IMNM?

Do insiders and institutionals hold more shares of DBVT or IMNM?

Do analysts rate DBVT or IMNM?

Summary

How does DBV Technologies compare to NewAmsterdam Pharma?

Does the media favor DBVT or NAMS?

Do insiders & institutionals have more ownership in DBVT or NAMS?

Which has more risk and volatility, DBVT or NAMS?

Is DBVT or NAMS more profitable?

Do analysts recommend DBVT or NAMS?

Which has higher earnings and valuation, DBVT or NAMS?

Summary

How does DBV Technologies compare to Zai Lab?

Do analysts recommend ZLAB or DBVT?

Do insiders and institutionals have more ownership in ZLAB or DBVT?

Does the media prefer ZLAB or DBVT?

Is ZLAB or DBVT more profitable?

Which has more risk & volatility, ZLAB or DBVT?

Which has better valuation and earnings, ZLAB or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools